<DOC>
	<DOC>NCT01981486</DOC>
	<brief_summary>PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days. Exploratory measures of PDE2 inhibition will also be evaluated in blood and blister fluid.</brief_summary>
	<brief_title>A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Healthy male and/or female (of nonchildbearing potential) subjects between the ages of 18 and 55 years Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs) Subjects with Gilbert's disease or screening laboratory test results that deviate from the upper and/or lower limits of the reference or acceptable range. The exception is that all liver function tests must not exceed the upper limit of normal. Subjects with evidence of, or history of, hepatic disorder, including acute or chronic hepatitis B or hepatitis C. Subjects with very light skin or very dark skin (at the discretion of the investigator).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>PF-05180999</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>migraine</keyword>
	<keyword>PDE2</keyword>
	<keyword>cAMP</keyword>
	<keyword>cGMP</keyword>
	<keyword>cantharidin</keyword>
	<keyword>blister</keyword>
	<keyword>CYP3A induction</keyword>
</DOC>